A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer
-
Published:2023-08-28
Issue:9
Volume:4
Page:1326-1344
-
ISSN:2662-1347
-
Container-title:Nature Cancer
-
language:en
-
Short-container-title:Nat Cancer
Author:
Chitty Jessica L.ORCID, Yam Michelle, Perryman Lara, Parker Amelia L., Skhinas Joanna N., Setargew Yordanos F. I., Mok Ellie T. Y., Tran Emmi, Grant Rhiannon D.ORCID, Latham Sharissa L.ORCID, Pereira Brooke A., Ritchie Shona C., Murphy Kendelle J., Trpceski Michael, Findlay Alison D., Melenec Pauline, Filipe Elysse C., Nadalini AudreyORCID, Velayuthar Sipiththa, Major GretelORCID, Wyllie Kaitlin, Papanicolaou MichaelORCID, Ratnaseelan Shivanjali, Phillips Phoebe A.ORCID, Sharbeen George, Youkhana Janet, Russo Alice, Blackwell AntoniaORCID, Hastings Jordan F., Lucas Morghan C., Chambers Cecilia R., Reed Daniel A.ORCID, Stoehr Janett, Vennin Claire, Pidsley Ruth, Zaratzian Anaiis, Da Silva Andrew M., Tayao Michael, Charlton Brett, Herrmann DavidORCID, Nobis Max, Clark Susan J., Biankin Andrew V.ORCID, Johns Amber L., Croucher David R.ORCID, Nagrial Adnan, Gill Anthony J., Grimmond Sean M.ORCID, Chantrill Lorraine A., Chou Angela, Dwarte Tanya, Metcalf Xanthe L., Jeong Gloria, Kenyon Lara, Waddell Nicola, Pearson John V., Patch Ann-Marie, Nones Katia, Newell Felicity, Mukhopadhyay Pamela, Addala Venkateswar, Kazakoff Stephen, Holmes Oliver, Leonard Conrad, Wood Scott, Hofmann Oliver, Samra Jaswinder S., Pavlakis Nick, Arena Jennifer, High Hilda A., Asghari Ray, Merrett Neil D., Das Amitabha, Cosman Peter H., Ismail Kasim, Stoita Alina, Williams David, Spigellman Allan, McLeo Duncan, Kirk Judy, Kench James G., Grimison Peter, Sandroussi Charbel, Goodwin Annabel, Mead R. Scott, Tucker Katherine, Andrews Lesley, Texler Michael, Forrest Cindy, Ballal Mo, Fletcher David, Beilin Maria, Feeney Kynan, Epari Krishna, Mukhedkar Sanjay, Zeps Nikolajs, Nguyen Nan Q., Ruszkiewicz Andrew R., Worthley Chris, Chen John, Brooke-Smith Mark E., Papangelis Virginia, Clouston Andrew D., Barbour Andrew P., O’Rourke Thomas J., Fawcett Jonathan W., Slater Kellee, Hatzifotis Michael, Hodgkinson Peter, Nikfarjam Mehrdad, Eshleman James R., Hruban Ralph H., Wolfgang Christopher L., Scarpa Aldo, Lawlor Rita T., Corbo Vincenzo, Bassi Claudio, Jamieson Nigel B., Chang David K., Dreyer Stephan B., Abdulkhalek Lea, Schmitz Tatjana, Lee Victoria, Stewart Kym Pham, Arshi Mehreen, Steinmann Angela M., Pajic MarinaORCID, Timpson PaulORCID, Jarolimek WolfgangORCID, Cox Thomas R.ORCID, ,
Abstract
AbstractThe lysyl oxidase family represents a promising target in stromal targeting of solid tumors due to the importance of this family in crosslinking and stabilizing fibrillar collagens and its known role in tumor desmoplasia. Using small-molecule drug-design approaches, we generated and validated PXS-5505, a first-in-class highly selective and potent pan-lysyl oxidase inhibitor. We demonstrate in vitro and in vivo that pan-lysyl oxidase inhibition decreases chemotherapy-induced pancreatic tumor desmoplasia and stiffness, reduces cancer cell invasion and metastasis, improves tumor perfusion and enhances the efficacy of chemotherapy in the autochthonous genetically engineered KPC model, while also demonstrating antifibrotic effects in human patient-derived xenograft models of pancreatic cancer. PXS-5505 is orally bioavailable, safe and effective at inhibiting lysyl oxidase activity in tissues. Our findings present the rationale for progression of a pan-lysyl oxidase inhibitor aimed at eliciting a reduction in stromal matrix to potentiate chemotherapy in pancreatic ductal adenocarcinoma.
Funder
Department of Health | National Health and Medical Research Council Cancer Council NSW Cancer Institute NSW Susan G. Komen Avner Pancreatic Cancer Foundation Perpetual IMPACT Maridulu Budyari Gumal Sydney Partnership for Health, Education, Research and Enterprise [SPHERE] Cancer Clinical Academic Group Senior Research Fellowship Human Frontier Science Program Cancer Australia Philip Hemstritch Pancreatic Cancer Fellowships Len Ainsworth Fellowship in Pancreatic Cancer Research Avner Pancreatic Cancer Foundation
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Reference61 articles.
1. Cox, T. R. The matrix in cancer. Nat. Rev. Cancer 21, 217–238 (2021). 2. Rahib, L. et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74, 2913–2921 (2014). 3. Piersma, B., Hayward, M.-K. & Weaver, V. M. Fibrosis and cancer: a strained relationship. Biochim. Biophys. Acta Rev. Cancer 1873, 188356 (2020). 4. Biffi, G. & Tuveson, D. A. Diversity and biology of cancer-associated fibroblasts. Physiol. Rev. 101, 147–176 (2021). 5. Hemmings, C. & Connor, S. Pathological assessment of tumour regression following neoadjuvant therapy in pancreatic carcinoma. Pathology 52, 621–626 (2020).
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|